Small bowel gastrointestinal stromal tumors (GISTs) account for 20%–30% of GISTs and are associated with more aggressive behavior than gastric lesions. Standard treatment for localized disease is R0 surgical resection with negative margins. Minimally invasive approaches have demonstrated oncologic outcomes comparable to those of open surgery, but technical descriptions of robotic resection incorporating adjunctive fluorescence imaging and intracorporeal anastomosis remain limited. This retrospective case review describes minimally invasive robotic small bowel GIST resection using indocyanine green (ICG) fluorescence to guide intraoperative perfusion assessment. Institutional review board authorization was obtained. Data on clinical presentation, diagnostic evaluation, operative technique, and postoperative outcomes were reviewed and used to prepare this case report. A 67-year-old male presented with abdominal discomfort and weight loss. Clinical workup included cross-sectional imaging, which showed a 3.9-cm distal small bowel mass without lymphadenopathy. The patient underwent endoscopic evaluation, which localized a proximal jejunal subepithelial lesion and included tattoo placement. Minimally invasive robotic surgical resection was performed. After mesenteric division, ICG near-infrared fluorescence confirmed adequate perfusion of the planned transection margins. A side-to-side functional end-to-end enteroenterostomy was completed intracorporeally, and the specimen was extracted in a protective specimen bag. The patient recovered without complications and was discharged on postoperative day 1. Pathology revealed a 3.9-cm low-grade spindle-cell GIST with negative margins. Robotic minimally invasive resection of a symptomatic small bowel GIST with intracorporeal anastomosis was feasible and consistent with established oncologic principles. ICG fluorescence imaging provided real-time perfusion assessment. Early multidisciplinary collaboration and selective diagnostic evaluation may help streamline care. This case illustrates the integration of advanced robotic platforms and fluorescence-guided near-infrared imaging in the management of small bowel GIST while maintaining adherence to established oncologic principles.
Subepithelial tumors (SETs) located at the gastroesophageal (GE) junction remain technically challenging in minimally invasive surgery because the convergence of the esophageal sphincter, diaphragmatic hiatus, and gastric fundus creates a confined operative field. When a tumor is fully embedded within the muscular layer, its capsular margin is often indistinguishable from the serosal surface, making precise enucleation technically demanding. To address this limitation, we adopted a fluorescence-guided technique that enables accurate intraoperative localization of the tumor through indocyanine green (ICG) injection. After induction of anesthesia, approximately 0.1–0.2 mL (0.05–0.1 mg) of ICG diluted in normal saline is injected endoscopically into the submucosal plane at the tumor site for benign SETs. During surgery, near-infrared visualization provides a distinct fluorescent margin that guides safe serosal incision and enucleation while preserving the mucosa and the anatomy of the GE junction. This technique is particularly useful for benign, well-encapsulated lesions such as leiomyoma or ectopic pancreas, where clear dissection planes can be preserved. However, it should not be used for lesions with any suspicion of gastrointestinal stromal tumor or other malignant potential, because capsular or intratumoral injection may pose a theoretical risk of tumor cell dissemination. Careful peritumoral submucosal injection that avoids capsular disruption may be cautiously considered. In selected benign tumors, ICG-guided serosal enucleation provides clear localization, facilitates complete resection, and minimizes both functional and structural complications at the GE junction.